Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Affinity and Avidity01:41

Affinity and Avidity

Overview
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic <i>HER2</i>-Mutant Non-Small Cell Lung Cancer.

JCO precision oncology·2026
Same author

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors.

JCO precision oncology·2026
Same author

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges.

Lung Cancer (Auckland, N.Z.)·2026
Same author

HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.

Lung Cancer (Auckland, N.Z.)·2026
Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026
Same author

Consideration of Enrollment Rates of Asian, Asian Pacific Islander, and Hispanic Patients in Non-small Cell Lung Cancer Trials.

Targeted oncology·2026
Same journal

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same journal

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Targeted oncology·2026
Same journal

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

Targeted oncology·2026
Same journal

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Targeted oncology·2026
Same journal

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026
Same journal

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Targeted oncology·2026
查看所有相关文章

相关实验视频

Updated: May 12, 2026

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology
07:13

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology

Published on: February 3, 2011

13.1K

用户指南的Amivantamabb.

Danielle Brazel1, Janellen Smith2, Sai-Hong Ignatius Ou2

  • 1Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA.

Targeted oncology
|February 4, 2025
PubMed
概括
此摘要是机器生成的。

阿米万他马布为具有特定EGFR exon20ins突变的非小细胞肺癌 (NSCLC) 提供了新的治疗选择. 本综述详细介绍了其使用,有效性和管理独特的副作用,以获得最佳的患者益处.

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

4.4K

相关实验视频

Last Updated: May 12, 2026

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology
07:13

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology

Published on: February 3, 2011

13.1K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

4.4K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学 是一个学科.
  • 免疫学 免疫学 免疫学

背景情况:

  • 在非小细胞肺癌 (NSCLC) 中表皮生长因子受体 (EGFR) exon20ins突变会对传统的氨酸激酶抑制剂产生耐药性.
  • 阿米万塔马布是一种新型疗法,通过多种机制,包括免疫细胞招募,向这些耐药突变.
  • 对于EGFR exon20ins NSCLC的前线和后线设置,以及对EGFR敏感性突变的组合疗法.

研究的目的:

  • 提供关于amivantamab的作用机制,药理学和临床试验数据的全面审查.
  • 为了指导临床医生管理与阿米万他马布治疗相关的独特毒性.
  • 为医疗保健专业人员和管理NSCLC患者的研究人员提供实用参考.

主要方法:

  • 对在NSCLC中使用amivantamab的已发表的临床试验数据的审查.
  • 对阿米万塔马布的药理性质和作用机制的分析.
  • 综合有关管理amivantamab相关副作用的信息.

主要成果:

  • 阿米万塔马布在患有EGFR exon20ins突变的NSCLC中表现出有效性,已在各种环境中获得批准.
  • 药物的独特机制涉及绕过抗性突变和引发免疫反应.
  • 与EGFR和MET途径抑制相关的amivantamab相关毒性的管理策略至关重要.

结论:

  • 阿米万他马布在治疗特定NSCLC亚型,特别是那些具有EGFR exon20ins突变的治疗中取得了重大进展.
  • 有效地管理amivantamab的副作用对于最大限度地提高治疗效益和患者的治疗结果至关重要.
  • 本综述为参与NSCLC向治疗的临床医生和研究人员提供了宝贵的见解.